Chemotherapy continues to be the preferred method of treatment for epilepsy, although alternatives such as surgery and electrical stimulation are available and other alternatives such as gene therapy are being explored . Despite the availability of approximately 30 approved drugs with a variety of different mechanisms of action, a significant fraction of epileptics are refractory to available treatments for epilepsy. GABA-T was selected as the target for rational drug design because it is a validated target for epilepsy ) . The only approved drug, Vigabatrin, that targets GABA-T is associated with serious adverse effects in some cases . Therefore, novel drugs designed to target GABA-T without such adverse effects have the potential to be useful individually, or in combination with other approved drugs. Combinations of drugs with different mechanisms of action for treatment of epilepsy have the potential for efficacy in patients that are refractory to treatment with drugs with a single mechanism of action . All of the current drugs are only approved for symptomatic treatment of epilepsy, i.e., they are not preventive or curative. It has been proposed that combinations of drugs with different mechanisms of action have the potential for prevention of epileptogenesis .